DNA同业对比
DNA 与SIC 2836 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DNA本股 | $450M#8 | — | 1.1x#2 | 2.6x#1 | -25.1%#7 | 42.8%#1 | -185.3%#2 | -0.1%#2 | — | — | — | — |
| FDMT | — | — | — | — | 230194.6%#1 | 12.9%#5 | -187.2%#3 | -34.4%#6 | -44.7%#2 | — | — | — |
| AURA | $698M#1 | — | 2.2x#7 | — | — | -22.2%#8 | — | -33.7%#5 | — | — | 6.8%#3 | — |
| ALLO | $579M#2 | — | 1.3x#4 | — | -100.0%#8 | 25.9%#3 | — | -43.8%#8 | — | — | 43.2%#2 | — |
| PRME | $546M#3 | — | 13.7x#15 | 117.9x#6 | 55.3%#4 | -2.7%#7 | -4498.1%#7 | -505.3%#15 | — | — | — | — |
| TECX | $544M#4 | — | 2.4x#9 | — | — | -27.9%#10 | — | -33125.9%#16 | -713.5%#5 | — | — | — |
| RGNX | $527M#5 | — | 7.3x#13 | 3.1x#2 | 104.5%#3 | 14.6%#4 | -94.6%#1 | -270.2%#14 | — | — | -13.9%#5 | — |
| EIKN | $460M#7 | — | 1.0x#1 | — | — | — | — | 0.0%#1 | — | — | — | — |
| ZURA | $444M#9 | — | 4.4x#12 | — | — | -31.0%#12 | — | -67.6%#10 | — | — | — | — |
| KYTX | $427M#10 | — | 2.6x#10 | — | — | -26.5%#9 | — | -97.4%#12 | -107.1%#3 | — | — | — |
| CCCC | $424M#11 | — | 1.7x#5 | 11.8x#5 | 1.0%#6 | 0.3%#6 | -320.5%#5 | -42.5%#7 | — | — | — | — |
| CABA | $420M#12 | — | 2.0x#6 | — | — | -44.9%#13 | — | -79.7%#11 | — | — | — | — |
| ARTV | $420M#13 | — | 1.2x#3 | — | -100.0%#8 | -28.3%#11 | — | -24.1%#4 | — | — | 262.7%#1 | — |
| EDIT | $418M#14 | — | 4.0x#11 | 10.3x#4 | 25.4%#5 | 32.5%#2 | -394.9%#6 | -152.0%#13 | — | — | -3.9%#4 | — |
| GRML | $477M#6 | — | 8.2x#14 | — | — | -71.6%#14 | — | -18.2%#3 | -14.6%#1 | — | — | — |
| XFOR | $349M#15 | 2.5x#1 | 2.2x#8 | 10.0x#3 | 1273.2%#2 | -111.5%#15 | -247.4%#4 | -50.9%#9 | -582.0%#4 | — | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-09-16。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议